Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.

Genomma enjoys broad-based growth in 2018, while NPD investments pay off for Hypera.

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."